Covid-19 booster shots take centre stage
Astra and Pfizer make the case for next-generation booster vaccines, which for the UK group at least could have important financial implications.
Amgen doubles down on bispecifics, courtesy of Teneobio
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
The markets refuse to forgive Infinity
The company’s second foray with a PI3K inhibitor shows signs of additive activity, but investors punish it all the same.
